Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies

NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.

A rare disease patient registry and data repository program developed by the National Institutes of Health could advance FDA efforts to understand rare disease natural histories and speed drug development in the space.

NIH could announce later this month the organizations that will participate in the pilot phase of the registry project

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America